白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应

doi:10.35541/cjd.20190858

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 170-173.doi: 10.35541/cjd.20190858

白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应

王若珺李若瑜

北京大学第一医院皮肤性病科北京大学真菌和真菌病研究中心皮肤病分子诊断北京市重点实验室 100034

收稿日期:2019-08-26 修回日期:2020-07-05 发布日期:2021-01-29
通讯作者: 李若瑜 E-mail:mycolab@126.com

Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis

Wang Ruojun, Li Ruoyu

Department of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing 100034, China

Received:2019-08-26 Revised:2020-07-05 Published:2021-01-29
Contact: Li Ruoyu E-mail:mycolab@126.com

摘要/Abstract

摘要： 【摘要】白细胞介素17A在银屑病的发生发展中具有关键作用。目前，有多种白细胞介素17A及其受体拮抗剂在多个国家上市并应用于银屑病的治疗，取得了明确疗效。然而，该类生物制剂在临床试验阶段及上市后，仍然有多项不良反应报道，包括上呼吸道感染、念珠菌感染、中性粒细胞减少和炎症性肠病等，严重者甚至可危及生命。本文综述3种白细胞介素17A及其受体拮抗剂司库奇尤单抗、ixekizumab和brodalumab的临床安全性。

关键词: 银屑病, 生物制剂, 白细胞介素17, 受体, 白细胞介素17, 抗体, 单克隆, 人, 药物毒性, 感染, 白色念珠菌

Abstract: 【Abstract】 Interleukin （IL）-17A plays a key role in the occurrence and development of psoriasis. At present, several marketed IL-17A and its receptor antagonists have been applied to the treatment of psoriasis, and definite therapeutic effects have been achieved. However, several adverse reactions, including upper respiratory tract infection, Candida infections, neutropenia, inflammatory bowel disease, which can be life-threatening, have been reported in clinical trials and after marketing of these biologics. This review summarizes clinical safety profiles of 3 types of interleukin-17A and its receptor antagonists, i.e., secukinumab, ixekizumab and brodalumab.

Key words: Psoriasis, Biological agents, Interleukin-17, Receptors, interleukin-17, Antibodies, monoclonal, humanized, Drug toxicity, Infection, Candida albicans

王若珺李若瑜. 白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应[J]. 中华皮肤科杂志, 2021,54(2):170-173. doi:10.35541/cjd.20190858

Wang Ruojun, Li Ruoyu. Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2021, 54(2): 170-173.doi:10.35541/cjd.20190858

参考文献 23

［1］	Gooderham M, Posso⁃De Los Rios CJ, Rubio⁃Gomez GA, et al. Interleukin⁃17 （IL⁃17） inhibitors in the treatment of plaque psoriasis: a review［J］. Skin Therapy Lett, 2015,20（1）:1⁃5.
［2］	Burkett PR, Kuchroo VK. IL⁃17 blockade in psoriasis［J］. Cell, 2016,167（7）:1669. doi: 10.1016/j.cell.2016.11.044.
［3］	李祥, 张小艳, 张理涛. 生物制剂治疗银屑病药物选择［J］. 中国中西医结合皮肤性病学杂志, 2019,18（1）:35⁃38. doi: 10. 3969/j.issn.1672⁃0709.2019.01.011.
［4］	Lockwood SJ, Prens LM, Kimball AB. Adverse reactions to biologics in psoriasis［J］. Curr Probl Dermatol, 2018,53:1⁃14. doi: 10.1159/000478072.
［5］	尹莉, 尹志强. 白介素⁃17家族与银屑病［J］. 中国麻风皮肤病杂志, 2017,33（1）:59⁃61.
［6］	Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis⁃⁃results of two phase 3 trials［J］. N Engl J Med, 2014,371（4）:326⁃338. doi: 10.1056/NEJMoa1314258.
［7］	van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long⁃term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:83⁃98.e4. doi: 10.1016/j.jaad.2016.03.024.
［8］	McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti⁃interleukin⁃17A monoclonal antibody, in patients with psoriatic arthritis （FUTURE 2）: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2015,386（9999）:1137⁃1146. doi: 10.1016/S0140⁃6736（15）61134⁃5.
［9］	Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med，2016，375（4）:345⁃356. doi:10.1056/NEJMoa1512711
［10］	Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis［J］. N Engl J Med, 2015,373（14）:1318⁃1328. doi: 10.1056/NEJMoa1503824.
［11］	Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate⁃to⁃severe plaque psoriasis: a systematic review and meta⁃analysis［J］. Clin Drug Investig, 2017,37（5）:439⁃451. doi: 10.1007/s40261⁃017⁃0500⁃9.
［12］	Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin⁃17 inhibitors and their practical management［J］. Br J Dermatol, 2017,177（1）:47⁃62. doi: 10.1111/bjd.15015.
［13］	Leonardi C, Matheson R, Zachariae C, et al. Anti⁃interleukin⁃17 monoclonal antibody ixekizumab in chronic plaque psoriasis［J］. N Engl J Med, 2012,366（13）:1190⁃1199. doi: 10.1056/NEJMoa 1109997.
［14］	Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double⁃blind, placebo⁃controlled study of brodalumab in patients with moderate⁃to⁃severe plaque psoriasis［J］. Br J Dermatol, 2016,175（2）:273⁃286. doi: 10.1111/bjd.14493.
［15］	Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment［J］. J Am Acad Dermatol, 2014,71（6）:1183⁃1190.e3. doi: 10.1016/j.jaad. 2014.08.039.
［16］	Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52⁃week, open⁃label study［J］. Br J Dermatol, 2017,176（3）:741⁃751. doi: 10.1111/bjd.14702.
［17］	Kamata M, Tada Y. Safety of biologics in psoriasis［J］. J Dermatol, 2018,45（3）:279⁃286. doi: 10.1111/1346⁃8138.14096.
［18］	Smith E, Stark MA, Zarbock A, et al. IL⁃17A inhibits the expansion of IL⁃17A⁃producing T cells in mice through "short⁃loop" inhibition via IL⁃17 receptor［J］. J Immunol, 2008,181（2）:1357⁃1364. doi: 10.4049/jimmunol.181.2.1357.
［19］	Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin⁃17 inhibition: role in psoriasis and inflammatory bowel disease［J］. J Dermatolog Treat, 2018,29（1）:13⁃18. doi: 10.1080/09546634. 2017.1329511.
［20］	王刚. 皮肤科生物制剂的主要不良反应及对策［J］. 中华皮肤科杂志, 2019,52（2）:77⁃80. doi: 10.3760/cma.j.issn.0412⁃4030. 2019.02.001.
［21］	Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti⁃interleukin⁃17⁃receptor antibody for psoriasis［J］. N Engl J Med, 2012,366（13）:1181⁃1189. doi: 10.1056/NEJMoa1109017.
［22］	AbuHilal M, Walsh S, Shear N. The role of IL⁃17 in the pathogenesis of psoriasis and update on IL⁃17 inhibitors for the treatment of plaque psoriasis［J］. J Cutan Med Surg, 2016,20（6）:509⁃516. doi: 10.1177/1203475416651605.
［23］	Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice［J］. Rheumatology （Oxford）, 2016,55（2）:210⁃220. doi: 10.1093/rheumatology/kev277.

[1]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[2]	张元文孙从乾潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024, 57(5): 471-475.
[3]	郭澜晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478.
[4]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[5]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[6]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[7]	何艳艳马骁惠云王雯竹王宝玺曾荣徐浩翔. 基于高通量测序对反常性痤疮中PPAR通路作用的初步探讨[J]. 中华皮肤科杂志, 2024, 57(4): 309-315.
[8]	裴璐郑娜娜曾荣谢媛媛徐浩翔段志敏刘宇甄李岷. 痤疮丙酸杆菌生物膜诱导角质形成细胞发生炎症反应的分子机制研究[J]. 中华皮肤科杂志, 2024, 57(4): 302-308.
[9]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[10]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429.
[11]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[12]	吴玉冰王晓宇安彬祎吴莹莹桑红孔庆涛. 环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子信号通路在银屑病发病中的作用[J]. 中华皮肤科杂志, 2024, 0(3): 20230394-e20230394.
[13]	朱婷婷张学军. 阿普米司特在斑块状银屑病治疗中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230448-e20230448.
[14]	郝丹王怡怡肖月闫薇李薇. [开放获取] 特殊部位银屑病系统治疗临床研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230190-e20230190.
[15]	姚我汪慧英. [开放获取] 拉那利尤单抗治疗遗传性血管性水肿临床试验的系统综述[J]. 中华皮肤科杂志, 2024, 0(3): 20230378-e20230378.

白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应

Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 23

相关文章 15

Metrics

本文评价

推荐阅读 10